Low-Affinity Anti-aP2 Antibodies for Stable Metabolic Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutic approaches for targeting adipocyte lipid-binding protein aP2 (aP2) have been challenging due to its high abundance in adipocytes, and high-affinity antibodies lead to increased circulating aP2 levels, complicating clinical translation for metabolic disorders.
Innovation Solution
Development of low-affinity anti-aP2 monoclonal antibodies and antigen binding agents that bind to secreted aP2 with a KD of ≥10−7 M, neutralizing aP2 activity without significantly altering total circulating levels, thereby treating aP2-mediated disorders such as diabetes, obesity, and cardiovascular disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-affinity anti-aP2 antibodies are used to neutralize aP2 activity, then aP2 biological activity is effectively blocked, but circulating aP2 levels increase which complicates clinical translation
Solution Approach 1:
The patent applies parameter changes by modifying the binding affinity parameter of the antibody. Instead of using high-affinity antibodies (low KD), the invention employs low-affinity antibodies with KD ≥10^-7 M. This parameter change allows the antibody to neutralize aP2 activity effectively while preventing the accumulation of circulating aP2 that occurs with high-affinity binding, thus resolving the technical contradiction.
2Object-affected harmful factors
If high-affinity antibodies bind to aP2, then aP2 neutralization is achieved, but this leads to increased circulating aP2 levels and potential adverse effects
Solution Approach 1:
The patent changes the binding affinity parameter to resolve this contradiction. By using antibodies with KD ≥10^-7 M (low affinity), the treatment effectively addresses aP2-mediated disorders through neutralization while avoiding the adverse effects associated with high-affinity binding, such as increased circulating aP2 levels and potential off-target effects.
3Quantity of substance
If low-affinity antibodies (KD ≥10^-7 M) are used to treat aP2-mediated disorders, then circulating aP2 levels remain stable and adverse effects are reduced, but the binding strength is weaker
Solution Approach 1:
The patent employs antibody fragments (Fab, scFv, single-domain antibodies) as simplified copies or versions of full-length antibodies. These fragments maintain the ability to bind aP2 with appropriate low affinity (KD ≥10^-7 M) while having reduced complexity. This allows effective neutralization of aP2 activity with stable circulating levels without requiring full antibody structure, compensating for the weaker binding through optimized fragment design.
4Force
If antibodies with KD <10^-7 M are used, then stronger binding occurs, but this increases circulating aP2 levels and complicates clinical translation
Solution Approach 1:
The patent establishes a specific parameter threshold (KD ≥10^-7 M) for antibody affinity to optimize clinical translation. By setting this boundary, the invention identifies antibodies that provide sufficient neutralization capacity while maintaining stable circulating aP2 levels, thereby simplifying the clinical translation process and avoiding the complexities associated with high-affinity antibodies.
Data Source
AI summary
This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.